Controlled trial of protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis.
A controlled trial with synthetic protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis was conducted in a total of 42 patients. The age, sex, etiology of pancreatitis, initial serum amylase level, and amylase creatinine clearance ratio were comparable between FOY-treated and control groups. FOY did not alter the course of the disease, but there was a weak trend toward lower morbidity and mortality in the FOY-treated patients. These results may justify further, larger scale studies or evaluation of alternate dosage or route of administration.
D000208:Acute Disease; D002986:Clinical Trials as Topic; D005260:Female; D016670:Gabexate; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010195:Pancreatitis / Q000188:drug therapy* / Q000401:mortality; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011897:Random Allocation
D006146:Guanidines; D011480:Protease Inhibitors; D016670:Gabexate